Abstract：Objective: To evaluate the effect of trimebutine combined with alprazolam on serum inflammatory factor, immune function, gastrointestinal hormone, ghrelin and quality of life of IBS-D patients. Methods: 117 cases of IBS-D were randomly divided into control group (n=58) and treatment group (n=59).The control group was only given trimebutine treatment, the treatment group was treated with trimebutine combined with alprazolam, 2 groups were consecutively treated for 4 weeks. Detected and compared of the 2 groups of serum inflammatory factors, immune function, gastrointestinal hormon, ghrelin and quality of life changes before and after treatment; Statistics and analysis of 2 groups of SF-36 quality of life scores before and after treatment. Results: After treatment, the MOT, GAS, SP, 5-HT, IL-8, IL-12, CD8+T cell ratio of 2 groups were significantly decreased (P<0.05 or P<0.01), VIP, SS, CCK, CGRP, IL-10, CD3+, CD4+, CD4+/CD8+ and SF-36 scores increased significantly (P<0.05 or P<0.01), and the difference between 2 groups was significant (P<0.05 or P<0.01). Conclusion: Trimebutine combined with alprazolam can significantly improve gastrointestinal peristaltic function of IBS-D patients, balance the level of inflammatory cytokines, improve the immune function and quality of life, with significant curative effect and worthy of clinical application.
杨永利, 宋春秋, 李红霞, 黄晓峰, 周红梅. 曲美布汀联合阿普唑仑对腹泻型IBS患者血清炎性因子及胃肠激素的临床研究[J]. 河北医学, 2017, 23(11): 1799-1802.
YANG Yongli, SONG Chunqiu, LI Hongxia, et al. Trimebutine Combined with Alprazolam on InflammatoryFactors and Gastrointestinal Hormones in Diarrhea Type IBS. HeBei Med, 2017, 23(11): 1799-1802.
2017, Vol. 23 
冀公网安备13080202000677号